Cargando…
Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
BACKGROUND: Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are approved in Europe as preventive treatment of migraine in patients with at least four monthly migraine days. Migraine gives rise to direct healthcare expenditures, but most of the economic burden of migraine is socio...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316628/ https://www.ncbi.nlm.nih.gov/pubmed/37400756 http://dx.doi.org/10.1186/s12883-023-03302-7 |